We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Read MoreHide Full Article
Key Takeaways
Ionis licensed ex-U.S. zilganersen rights to Recordati while retaining exclusive U.S. commercialization.
IONS will receive $30M upfront, milestone payments and tiered royalties on ex-U.S. net sales.
Zilganersen's FDA filing is under review for Alexander disease, with a decision due by Sept. 22, 2026.
Ionis Pharmaceuticals (IONS - Free Report) signed a license agreement with Italy-based Recordati. Per the terms, Recordati will acquire exclusive rights to develop and market its wholly owned investigational drug, zilganersen, outside the United States.
A regulatory filing is currently under review with the FDA, seeking approval for the drug to treat Alexander disease (AxD), a rare, progressive and often fatal neurological disorder. A final decision is expected by Sept. 22, 2026.
If approved, zilganersen, an RNA-targeted therapy, would become Ionis’ third wholly owned approved drug, joining Tryngolza (for severe hypertriglyceridemia) and Dawnzera (for HAE). It would also mark Ionis’ commercial entry into the neurology space, diversifying its commercial portfolio of wholly owned products.
Under the terms of the agreement, Recordati will assume responsibility for regulatory filings and commercialization of zilganersen across ex-U.S. markets, while Ionis will retain exclusive commercialization rights in the United States.
In exchange, Ionis will receive $30 million as an upfront payment and will be eligible for milestone payments. The company will also earn tiered royalties of up to the mid-20% range on annual ex-U.S. net sales of zilganersen.
Zilganersen's Potential Backed by Positive Clinical Data
The FDA filing is supported by positive results from a pivotal late-stage study evaluating zilganersen in children and adults living with AxD. The study met its primary endpoint; patients who received a 50 mg dose of zilganersen achieved a statistically significant and clinically meaningful stabilization in gait speed compared with control. Treatment with the candidate also demonstrated a favorable safety and tolerability profile.
AxD is a rare neurological disease that affects astrocytes, a type of brain cell that plays multiple roles in supporting neurons and oligodendrocytes. People living with this condition experience cognitive dysfunction and progressive neurologic deterioration, including difficulty swallowing and the inability to control muscles for large movements. There are currently no disease-modifying medicines approved for AxD patients.
If approved, zilganersen would be the first disease-modifying treatment for AxD.
IONS Stock Performance
Year to date, Ionis’ shares have lost 1% compared with the industry’s nearly 6% decline.
While the licensing agreement provides Ionis with an upfront payment and the potential for future milestone and royalty income, it underscores the company's broader commercial strategy. Rather than out-licensing zilganersen globally, Ionis has retained exclusive commercialization rights in the United States, while entrusting Recordati with regulatory and commercial responsibilities in international markets.
This structure allows Ionis to preserve the long-term value of the U.S. market, the largest commercial opportunity for the therapy, while leveraging Recordati's established infrastructure in rare diseases to expand zilganersen's reach outside the country.
The agreement aligns with Ionis' strategy of partnering with established companies to commercialize its wholly owned medicines outside the United States. Last year, the company granted Sweden-based Sobi exclusive rights to commercialize Tryngolza in markets outside the United States, Canada and China. Ionis entered into a similar licensing agreement with Japan-based Otsuka Pharmaceutical to market Dawnzera across Europe and Asia Pacific. These partnerships enable Ionis to broaden the global reach of its therapies while maintaining a focused commercial presence in its home market.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost 12% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.56 to $4.27. INDV’s shares are up 15% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.
View the Zacks #1 Rank List
Image: Bigstock
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Key Takeaways
Ionis Pharmaceuticals (IONS - Free Report) signed a license agreement with Italy-based Recordati. Per the terms, Recordati will acquire exclusive rights to develop and market its wholly owned investigational drug, zilganersen, outside the United States.
A regulatory filing is currently under review with the FDA, seeking approval for the drug to treat Alexander disease (AxD), a rare, progressive and often fatal neurological disorder. A final decision is expected by Sept. 22, 2026.
If approved, zilganersen, an RNA-targeted therapy, would become Ionis’ third wholly owned approved drug, joining Tryngolza (for severe hypertriglyceridemia) and Dawnzera (for HAE). It would also mark Ionis’ commercial entry into the neurology space, diversifying its commercial portfolio of wholly owned products.
Under the terms of the agreement, Recordati will assume responsibility for regulatory filings and commercialization of zilganersen across ex-U.S. markets, while Ionis will retain exclusive commercialization rights in the United States.
In exchange, Ionis will receive $30 million as an upfront payment and will be eligible for milestone payments. The company will also earn tiered royalties of up to the mid-20% range on annual ex-U.S. net sales of zilganersen.
Zilganersen's Potential Backed by Positive Clinical Data
The FDA filing is supported by positive results from a pivotal late-stage study evaluating zilganersen in children and adults living with AxD. The study met its primary endpoint; patients who received a 50 mg dose of zilganersen achieved a statistically significant and clinically meaningful stabilization in gait speed compared with control. Treatment with the candidate also demonstrated a favorable safety and tolerability profile.
AxD is a rare neurological disease that affects astrocytes, a type of brain cell that plays multiple roles in supporting neurons and oligodendrocytes. People living with this condition experience cognitive dysfunction and progressive neurologic deterioration, including difficulty swallowing and the inability to control muscles for large movements. There are currently no disease-modifying medicines approved for AxD patients.
If approved, zilganersen would be the first disease-modifying treatment for AxD.
IONS Stock Performance
Year to date, Ionis’ shares have lost 1% compared with the industry’s nearly 6% decline.
Image Source: Zacks Investment Research
Recordati Deal Reinforces Ionis' U.S.-First Commercial Strategy
While the licensing agreement provides Ionis with an upfront payment and the potential for future milestone and royalty income, it underscores the company's broader commercial strategy. Rather than out-licensing zilganersen globally, Ionis has retained exclusive commercialization rights in the United States, while entrusting Recordati with regulatory and commercial responsibilities in international markets.
This structure allows Ionis to preserve the long-term value of the U.S. market, the largest commercial opportunity for the therapy, while leveraging Recordati's established infrastructure in rare diseases to expand zilganersen's reach outside the country.
The agreement aligns with Ionis' strategy of partnering with established companies to commercialize its wholly owned medicines outside the United States. Last year, the company granted Sweden-based Sobi exclusive rights to commercialize Tryngolza in markets outside the United States, Canada and China. Ionis entered into a similar licensing agreement with Japan-based Otsuka Pharmaceutical to market Dawnzera across Europe and Asia Pacific. These partnerships enable Ionis to broaden the global reach of its therapies while maintaining a focused commercial presence in its home market.
Ionis Pharmaceuticals, Inc. Price
Ionis Pharmaceuticals, Inc. price | Ionis Pharmaceuticals, Inc. Quote
IONS’ Zacks Rank
Ionis currently carries a Zacks Rank #3 (Hold).
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Immunocore (IMCR - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost 12% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.56 to $4.27. INDV’s shares are up 15% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.